QIAGEN N.V. (QGEN) Stock Price & Overview

NYSE:QGEN • NL0015002SN0

Current stock price

41.03 USD
+0.65 (+1.61%)
At close:
41.03 USD
0 (0%)
After Hours:

The current stock price of QGEN is 41.03 USD. Today QGEN is up by 1.61%. In the past month the price decreased by -11.65%. In the past year, price increased by 1.88%.

QGEN Key Statistics

52-Week Range38.795 - 57.815
Current QGEN stock price positioned within its 52-week range.
1-Month Range38.795 - 45.91
Current QGEN stock price positioned within its 1-month range.
Market Cap
8.455B
P/E
16.61
Fwd P/E
15.77
EPS (TTM)
2.47
Dividend Yield
0.67%

QGEN Stock Performance

Today
+1.61%
1 Week
+3.32%
1 Month
-11.65%
3 Months
-13.75%
Longer-term
6 Months -16.71%
1 Year +1.88%
2 Years -7.92%
3 Years -15.25%
5 Years -21.44%
10 Years +62.11%

QGEN Stock Chart

QIAGEN N.V. / QGEN Daily stock chart

QGEN Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to QGEN. When comparing the yearly performance of all stocks, QGEN is a bad performer in the overall market: 76.3% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

QGEN Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to QGEN. QGEN scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QGEN Earnings

On February 5, 2026 QGEN reported an EPS of 0.62 and a revenue of 540.42M. The company missed EPS expectations (-3.03% surprise) and missed revenue expectations (-0.31% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 5, 2026
PeriodQ4 / 2025
EPS Reported$0.62
Revenue Reported540.42M
EPS Surprise -3.03%
Revenue Surprise -0.31%

QGEN Forecast & Estimates

24 analysts have analysed QGEN and the average price target is 55.35 USD. This implies a price increase of 34.9% is expected in the next year compared to the current price of 41.03.

For the next year, analysts expect an EPS growth of 5.2% and a revenue growth 6.7% for QGEN


Analysts
Analysts72.5
Price Target55.35 (34.9%)
EPS Next Y5.2%
Revenue Next Year6.7%

QGEN Groups

Sector & Classification

QGEN Financial Highlights

Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.47. The EPS increased by 10.63% compared to the year before.


Income Statements
Revenue(TTM)2.09B
Net Income(TTM)424.88M
Industry RankSector Rank
PM (TTM) 20.33%
ROA 6.76%
ROE 11.25%
Debt/Equity 0.44
Chartmill High Growth Momentum
EPS Q2Q%1.64%
Sales Q2Q%3.69%
EPS 1Y (TTM)10.63%
Revenue 1Y (TTM)5.65%

QGEN Ownership

Ownership
Inst Owners74.12%
Shares206.07M
Float205.16M
Ins Owners0.44%
Short Float %2.98%
Short Ratio2.3

About QGEN

Company Profile

QGEN logo image QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Company Info

IPO: 1996-09-01

QIAGEN N.V.

Hulsterweg 82

Venlo LIMBURG 5912 NL

CEO: Thierry Bernard

Employees: 5654

QGEN Company Website

QGEN Investor Relations

Phone: 31773556600

QIAGEN N.V. / QGEN FAQ

Can you describe the business of QIAGEN N.V.?

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.


Can you provide the latest stock price for QIAGEN N.V.?

The current stock price of QGEN is 41.03 USD. The price increased by 1.61% in the last trading session.


Does QIAGEN N.V. pay dividends?

QIAGEN N.V. (QGEN) has a dividend yield of 0.67%. The yearly dividend amount is currently 0.25.


What is the ChartMill rating of QIAGEN N.V. stock?

QGEN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Can you provide the sector and industry classification for QIAGEN N.V.?

QIAGEN N.V. (QGEN) operates in the Health Care sector and the Life Sciences Tools & Services industry.


Can you provide the growth outlook for QIAGEN N.V.?

The Revenue of QIAGEN N.V. (QGEN) is expected to grow by 6.7% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is QIAGEN N.V. worth?

QIAGEN N.V. (QGEN) has a market capitalization of 8.46B USD. This makes QGEN a Mid Cap stock.